Lazard Asset Management
TEVA icon

Lazard Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Lazard Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,484
Closed -$24K – 2301
2025
Q2 		$24K Sell
1,484
-86,792
-98% -$1.4M ﹤0.01% 2108
2025
Q1 		$1.36M Sell
88,276
-14,954
-14% -$267K ﹤0.01% 1097
2024
Q4 		$2.27M Sell
103,230
-134,053
-56% -$2.44M ﹤0.01% 834
2024
Q3 		$4.28M Sell
237,283
-302,477
-56% -$5.29M 0.01% 675
2024
Q2 		$8.77M Buy
539,760
+470,582
+680% +$7.25M 0.01% 540
2024
Q1 		$976K Sell
69,178
-36,561
-35% -$461K ﹤0.01% 931
2023
Q4 		$1.1M Hold
105,739
– – ﹤0.01% 933
2023
Q3 		$1.08M Buy
+105,739
New +$985K ﹤0.01% 963
2018
Q4 		– Sell
-261
Closed -$5K – 1087
2018
Q3 		$5K Buy
+261
New +$6.06K ﹤0.01% 1013
2017
Q4 		– Sell
-21,336
Closed -$375K – 1108
2017
Q3 		$375K Sell
21,336
-2,002
-9% -$45K ﹤0.01% 735
2017
Q2 		$775K Sell
23,338
-44,767
-66% -$1.39M ﹤0.01% 677
2017
Q1 		$2.18M Sell
68,105
-10,138,619
-99% -$346M ﹤0.01% 646
2016
Q4 		$370M Sell
10,206,724
-7,146,652
-41% -$285M 0.75% 43
2016
Q3 		$798M Buy
17,353,376
+1,766,513
+11% +$92.2M 1.59% 13
2016
Q2 		$783M Buy
15,586,863
+1,122,827
+8% +$59.8M 1.65% 13
2016
Q1 		$774M Buy
14,464,036
+686,385
+5% +$40.3M 1.69% 13
2015
Q4 		$904M Buy
13,777,651
+930,085
+7% +$57.5M 2.07% 7
2015
Q3 		$725M Sell
12,847,566
-4,759,161
-27% -$309M 1.73% 13
2015
Q2 		$1.04B Sell
17,606,727
-2,496,502
-12% -$154M 2.18% 3
2015
Q1 		$1.25B Buy
20,103,229
+1,046,010
+5% +$60.8M 2.7% 1
2014
Q4 		$1.1B Buy
19,057,219
+1,237,198
+7% +$68.9M 2.34% 1
2014
Q3 		$958M Buy
17,820,021
+2,537,019
+17% +$134M 2.06% 4
2014
Q2 		$801M Buy
15,283,002
+10,288,361
+206% +$526M 1.67% 8
2014
Q1 		$264M Sell
4,994,641
-369,884
-7% -$17.1M 0.59% 50
2013
Q4 		$215M Buy
5,364,525
+1,784,165
+50% +$70.3M 0.48% 65
2013
Q3 		$135M Sell
3,580,360
-214,777
-6% -$8.38M 0.32% 83
2013
Q2 		$149M Buy
+3,795,137
New +$148M 0.35% 74

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Lazard Asset Management's TEVA Position: Q3 2025 in Review

Lazard Asset Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2025, closing a stake of 1,484 shares — an estimated $24K sold.

Lazard Asset Management first reported a position in TEVA in Q2 2013 and held it in 27 quarters. The position peaked at $1.25B in Q1 2015. 550 funds tracked by Wall St. Rank hold TEVA as of Q3 2025.

  • Lazard Asset Management reported no remaining Teva Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Lazard Asset Management sold 1,484 Teva Pharmaceuticals shares in Q3 2025, an estimated $24K.
  • Lazard Asset Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 27 quarters.
  • Lazard Asset Management's Teva Pharmaceuticals position peaked at $1.25B in Q1 2015.
  • 550 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2025.

Based on Lazard Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.